To include your compound in the COVID-19 Resource Center, submit it here.

Scios, Quintiles in Natrecor alliance

QTRN will provide $35 million to commercialize SCIO's Natrecor nesiritide for acute decompensated congestive heart failure,

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE